Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Guardant Health and Hikma Collaborate to Expand Precision Oncology Reach

NextEdge Admin

09 Dec 2023

2 min 42 sec

Guardant Health, Inc. (Nasdaq: GH) and Hikma Pharmaceuticals PLC (Hikma) have entered into a partnership to promote Guardant Health’s liquid and tissue biopsy tests for cancer screening, recurrence monitoring, and tumor mutation profiling across the Middle East and North Africa (MENA). This collaboration expands Guardant Health’s global reach and aims to enhance access to its next-generation sequencing (NGS) tests in the MENA region, where cancer cases are expected to double by 2040.

The portfolio of tests includes Shield™ for cancer screening, Guardant Reveal™ for minimal residual disease detection and recurrence monitoring, and Guardant360® and Guardant360 TissueNext™ for comprehensive genomic profiling across all solid cancers. The partnership leverages Hikma’s commercial capabilities and regional expertise to provide oncologists in MENA with advanced tools for various stages of cancer care.

Guardant Health, a precision oncology company, serves over 60 countries globally, and the collaboration with Hikma aligns with their commitment to improving patient outcomes by offering NGS tests throughout the cancer care continuum. The goal is to facilitate early cancer detection when it is most treatable.

Hikma, a multinational pharmaceutical company with a strong presence in the MENA region, sees the partnership as an opportunity to transform cancer care in the region. With a comprehensive oncology portfolio, including generics, biologics, immunotherapy, and innovations, Hikma aims to advance precision medicine for improved treatment outcomes in cancer patients.

This collaboration is particularly crucial as the prevalence of cancer is expected to rise in MENA, emphasizing the importance of timely and effective diagnostic tools and treatments. Both companies are dedicated to shaping a healthier world and enriching communities through innovative solutions and high-quality healthcare offerings.